SA
Sai Parenterals Ltd (SAIPARENT)
₹498.70
Mkt cap
₹2,256 Cr
P/E ratio
109.00
P/B
—
Div yield
0.00%
ROE
4.88%
ROCE
5.28%
EPS (TTM)
₹4.58
Book value
—
52W range
400–706
Sector
Healthcare
Price history
Previous close
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing. [1]
NSE SAIPARENTBSE 544742
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthHigh
TechnicalsNeutral
52-week range
−29.36% from high₹499
₹400+24.68% from low₹706
Current
₹498.70
Prev close
₹523.65
Day
−4.76%
Price performance
1D
−5.47%
1W
−1.78%
1M
−3.99%
3M
−18.89%
6M
—
1Y
—
YTD
+22.92%
Financials
Revenue, profit & margin
P/E ratio
109.0×
SAIPARENT is 215% above the sector median of 34.6×
SAIPARENT109.0×
Sector median34.6×
| Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|
| Sales | 33.39 | 96.15 | 197.93 | 178.67 | |
| Expenses | 28.65 | 99.71 | 171.83 | 155.15 | |
| Operating Profit | 4.74 | -3.56 | 26.10 | 23.52 | |
| OPM % | 14.20% | -3.70% | 13.19% | 13.16% | |
| Other Income | 1.17 | 3.13 | 2.88 | 3.74 | |
| Interest | 2.46 | 5.41 | 8.40 | 9.36 | |
| Depreciation | 1.45 | 5.79 | 8.18 | 8.11 | |
| Profit before tax | 2.00 | -11.63 | 12.40 | 9.79 | |
| Tax % | 29.50% | -42.65% | -6.13% | 19.00% | |
| Net Profit | 1.42 | -6.66 | 13.16 | 7.92 | |
| EPS in Rs | 0.52 | -1.80 | 2.98 | 1.79 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −3.68% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 11 Aug '26◦ |
| Earnings day | −3.68% |
| +1 day | −1.80% |
| +5 days | −5.77% |
| +15 days | −10.10% |
| +30 days | −11.70% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202651.16%Promoter
Promoters51.16%
FIIs4.03%1.70
DIIs8.52%4.34
Public36.29%6.04
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Sai Parenteral's | ₹510.75 | 108.69 | 2,256 | 0.00% | 8 | +457.75% | 179 | +435.10% | 5.28% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports1
Concall transcripts5
Announcements5
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 10 Sep - Sai Parenterals’ 10 Sep 2026 AGM resolutions, including director reappointments and secretarial auditor appointment, passed.Shareholder Meeting / Postal Ballot-Outcome of AGM 10 Sep - 25th AGM held on 10 Sep 2026; 12 resolutions passed, including IPO proceeds variation and management appointments.Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order 25 Aug - Subsidiary renewed 3-year OTC supply deal with Australian pharmacy chain worth AUD 30 million (~Rs204 crore).Announcement under Regulation 30 (LODR)-Press Release / Media Release 25 Aug - Noumed renewed a 3-year OTC supply deal with an Australian pharmacy chain, worth AUD 30 million.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 25 Aug - Intimation of schedule of Analyst/Institutional Investors Meeting scheduled to be held on 31st August, 2026